ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.

ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.

ALK inhibitor crizotinib has shown potent antitumor activity in children with refractory Anaplastic Large Cell Lymphoma (ALCL) and the opportunity to include ALK inhibitors in first-line therapies is oncoming. However, recent studies suggest that crizotinib-resistance mutations may emerge in ALCL pa...

Full description

Bibliographic Details
Main Authors: Federica Lovisa, Giorgio Cozza, Andrea Cristiani, Alberto Cuzzolin, Alessandro Albiero, Lara Mussolin, Marta Pillon, Stefano Moro, Giuseppe Basso, Angelo Rosolen, Paolo Bonvini
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4395299?pdf=render

Internet

http://europepmc.org/articles/PMC4395299?pdf=render

Similar Items